Background: Skin cancer is the most common other primary cancer in patients with lymphoma. However, an intriguing association between cutaneous lymphoma and other primary cancers has been suggested in a few studies. Objective: This study investigated other primary cancers in patients with cutaneous lymphoma to evaluate the risk for occurrence of each type of cancer. Methods: We screened for other primary cancers in 428 patients with cutaneous lymphoma. Clinical features were analyzed according to the lineage and origin of the lymphomas. We calculated the standardized incidence ratio with statistical analysis for each group according to age. Results: Among 330 patients with cutaneous T cell lymphoma and 98 with cutaneous B cell lymphoma, a total of 43 cancers in 38 patients were finally included. Other primary cancers were prevalent in patients with cutaneous B cell lymphoma and patients with secondary cutaneous lymphoma. However, those differences were not significant when the age was calibrated by multiple logistic regression. Metachronously higher standardized incidence ratios were observed for primary lung (standardized incidence ratio [SIR] 
INTRODUCTION
Cutaneous lymphomas (CLs) are a diverse group of rare diseases characterized by cutaneous infiltration of malignant lymphocytic cells [1] [2] [3] . CL is generally divided into two subcategories: primary and secondary CL. Primary CLs (PCLs) are the second most common extranodal non-Hodgkin lymphomas. Secondary CLs (SCLs) are defined as systemic lymphoma accompanied by secondary spread to the skin 1, 3, 4 . Several epidemiological studies have demonstrated differences in the relative frequency and characteristics of CL in various regions, including the United States, Europe, and the Asia-Pacific region [1] [2] [3] .
Likewise, other primary cancers in patients with CL may be different according to epidemiologic background. Several studies have evaluated the characteristics of other primary cancers in patients with primary cutaneous T cell lymphoma (PCTCL) [4] [5] [6] [7] [8] [9] and primary cutaneous B cell lymphoma (PCBCL) 10 . However, an association between CL and other primary cancers has yet to be examined. Furthermore, there have not been any studies focused on Asian patients. The aim of the present study is to evaluate the relationship between CL and other primary cancers. We analyzed the entire history of other primary cancers in 
Variables of interest
The following clinical data were collected from patient medical records: age, sex, site of lesion, duration of diagnosis, subtype of CL, types of other primary cancer, interval between onset of CL and other primary cancer, and survival. Histopathological diagnosis of primary cancer was made by excluding the possibility of metastasis from other cancers. By defining those cancers diagnosed more than 2 months after diagnosis of CL as metachronous primary cancers, the possibility of selection bias was minimized. Cancers diagnosed 2 or more months before the diagnosis of CL were considered prechronous cancers, whereas those cancers diagnosed within 2 months were synchronous primary cancers 11 .
Statistical analysis
All data were statistically analyzed by using PASW Statistics ver. 18.0 (IBM Co., Armonk, NY, USA). The p-values ＜0.05 were considered statistically significant.
We used t-test and analysis of variance to investigate differences between group means. The chi-square, Fisher exact tests and multiple logistic regression were used to analyze differences between groups. The relative risk of developing a metachronous primary cancer was evaluated by using SIRs 11, 12 . SIR is defined as the ratio of observed number of cancers divided by the expected number of cancers. The expected number of each cancer was generated by multiplying the person-years by the age-and sex-specific incidence rates for each cancer.
The age-and sex-specific incidence rates of each cancer in general population were collected from the annual survey of National Cancer Information Center in year of 2014 13 .
The statistical significance of the SIR was analyzed using the Poisson distribution and calculated 95% confidence intervals (CIs).
RESULTS

Patient characteristics of cutaneous lymphoma
Among 428 patients with CL, there were 318 (74.3%) patients with PCL and 110 (25.7%) with SCL. The average age at diagnosis was 45.4 years (median age, 47 years). There were 240 male and 188 female patients, with a (Table 3) . Gastrointestinal cancers were common in patients with PCL (n=7), whereas prostate (n=3) and lung (n=2) cancers were common in patients with SCL. According to the histologic lineages, CTCL most frequently accompanied gastrointestinal cancers (n=6), followed by skin cancers (n=4) and thyroid cancers (n=3). CBCL most frequently accompanied gastrointestinal cancers (n=5), followed by prostate cancers (n=3) and lung cancers (n=2).
Primary cancers arising metachronously (＞2 months after lymphoma) in patients with cutaneous lymphoma
In the 428 patients with CL, 13 (3.0%) metachronous primary cancers were observed. Nine (2.1%) were in patients with CTCL and 4 (0.9%) in patients with CBCL. The average age at diagnosis of CL was 60.4 years (median age, 64 years). Lung (n=3) and skin (n=3) cancers were the most common metachronous primary cancers. All skin cancers were non-malanoma skin cancers including angiosarcoma (n=1), Kaposi sarcoma (n=1), basal cell carcinoma (n=1 (Table 4) 12 .
DISCUSSION
In this study, we retrospectively analyzed other primary cancers in Korean patients with CL. Although previous studies dealt with the specific lineages of CL, we surveyed all patients with CL and classified them for stratified analysis. The risk of other primary cancers is generally increased in patients with CTCL [4] [5] [6] [7] [8] [9] [10] 14 . The percentages of other primary cancers in patients with CTCL estimated in several studies ranged from 5.5% to 11.2% 8, 14 , with a relative risk of 1.04 to 2.4 5, 9 . In this study, 28 (8.5%) other primary cancers were observed in patients with CTCL. In a review of 672 patients with CTCL at the M.D. Anderson Cancer Center between 1979 and 1999, 112 (16.6%) had at least one additional cancer, with 37 (5.5%) that occurred after the diagnosis of CTCL, and the relative risk was estimated as a 1.79-fold risk 8 . In regards to the types of predominant metachronous cancers, non-Hodgkin lymphoma, Hodgkin lymphoma, lung 7, 14 , colon 7 , biliary 5 , and vulvar 8 cancers have been reported. Most recently, Amber et al. 4 found 183 other primary cancers (6.3%) in a total of 2,923 cases of CTCL, with the SIR of 1.38 and, in their report, non-Hodgkin and Hodgkin lymphomas were the most predominant metachronous other primary cancers. In addition, the increased risks for bronchopulmonary cancers in female patients and urinary system cancers in patients with CD30 + cutaneous T cell lymphoproliferative diseases were newly noted 4 . We observed a total of 9 (2.7%) metachronous other primary cancers in 330 patients with CTCL. Considering the patients with CD30 + cutaneous T cell lymphoproliferative diseases, breast cancers (n=2), skin cancer (n=2; Kaposi sarcoma, angiosarcoma), and pancreatic cancer (n=1) were metachronously noted in a total of 91 patients, which is different from previously reported data. Unlike previous studies, we included non-melanoma skin cancers, suggesting an unreported or underestimated relationship between other primary non-melanoma skin cancers in CL.
In regard to CBCL, the only available cohort study was recently performed, and showed a high rate of other primary cancers (25.5%) 10 . However, we observed only 4 (4.1%) metachronous other primary cancers in 98 patients with CBCL. When including prechronous and synchronous other primary cancers, only 15 other primary cancers (15.3%) were detected, which is still lower than in the previous report. More studies are required to determine whether other primary cancers are more frequent in patients with CBCL. The SCL group showed higher frequency for other primary cancers than the PCL group. The same tendency was observed when we focused on metachronous primary cancers, which also had a higher frequency in the SCL group than in the PCL group. The overall incidences of other primary cancers in the present study in patients with CL were lower than those in previous studies [4] [5] [6] [7] [8] [9] [10] 14 . The reason for this relative lower risk might be derived from the ethnic difference and small sample size. Moreover, since this study was based on the single-centred study, it might cause the missing data and selection bias. Some of the previously reported literature did not clearly describe the sequence of diagnosis between CL and the other primary cancer. This point additionally might contribute to differences in stratified risk comparison. To demonstrate the more exquisite differences, further clinicoepidermiologic data are needed. Two main hypotheses have been suggested to explain the vulnerability of patients with CL to other primary cancers. The first is the changes in functional T-cell subsets caused by a shift towards clonal T cells 4 . The relatively decreased number of interferon-γ-secreting T cells in patients with CTCL supports this hypothesis 15 . That deficiency in T cells of patients with Sézary syndrome is similar to that of patients with advanced acquired immunodeficiency syndrome (AIDS) also supports this hypothesis 16 . The second hypothesis is that chemotherapies for CL weaken the immune systems of patients with CL to other primary cancers 4, 6, 10 . The incidence of other primary cancers in CTCL is highest within the first year of diagnosis 4 , supporting the role of immune dysfunction, rather than the influence of treatment for CL. One of the main objectives of this study was to explore the time interval between the diagnosis of CL and the diagnosis of other primary cancers to determine which hypothesis is more suitable to explain the risk of other primary cancers. Our data revealed a mean interval of 38.0 months in patients with CTCL, which is longer than previously reported 4 . Therefore, the influence of cytotoxic or chemotherapies in CL should not be ignored.
Although the overall incidence rate was measured lower than expected, the SIR for metachronous cancers is notable. The SIR was significantly higher in both sexes, irrespective of age (Table 4 ). In addition, the SIR of lung cancer, skin cancer and breast cancer were significantly higher. Recently, the deficiencies in the DNA repair pathways and chromosomal instability have been suggested as key factors in the development of CTCL 17 . This is supported by the fact that the expression of Ku70, which is involved in non-homologous end joining DNA repair, is significantly reduced in the T cells of patients with CTCL 18, 19 .
The significantly prolonged repair time of damaged DNA in the lymphocytes of patients with CTCL also supports this 17 . Deficiencies in DNA repair proteins such as Ku70/Ku80 have also been suggested as a causal factor in lung cancer 20 and breast cancer 18, 21 , and even in non-melanoma skin cancers 22 , which showed significantly higher SIR in patients with CL in our study. Although the underlying mechanisms are not fully understood, deficiency of DNA repair could be conceivable as the central concept for multiple cancer occurrences in patients with CL. Further genetic studies, including polymorphisms of the DNA repair genes in CL and other cancers, may help to better understand the cause and effect relationship. In conclusion, to the best of our knowledge, our study is the first report of the incidence of other primary cancers in Korean patients with cutaneous lymphoma. This study bears some limitations, such as being a retrospective study and having a small number of cases, along with being a single centre-based study. More patients are needed to shed further light on the association between CL and other primary cancers. Overall, for patients with CL, careful follow-up examinations are truly needed to detect other cancers as soon as possible.
